Pieris and Allergan enter anticalin collaboration agreement
Freising – German company Pieris AG has bagged a USD10m upfront payment from US drug delivery specialist Allergan for the worldwide exclusive licence for Pieris’ anticalin technology and its application against serious ocular disorders. Anticalins are synthetic, robust and small (20kDa) antibody-like molecules derived from naturally occurring lipid transport proteins. These can bind antigens or small molecules, and are very cheap to produce in comparison to antibody drugs. Under the terms of the agreement, Pieris will work with Allergan to both optimise existing and to design novel anticalins. Pieris currently has two VEGF inhibitors in advanced preclinical development, for example as treatment for age-related macular degeneration (AMD). Allergan will take over all discovery, development and commercialisation costs, and will be responsible for clinical development.